midazolam and dabigatran

midazolam has been researched along with dabigatran in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Bateman, KP; Chavez-Eng, CM; Goykhman, D; Lutz, RW	1
Bairlein, M; Denner, K; Fricke, R; Gieschen, H; Graudenz, K; Korjamo, T; Koskinen, M; Prien, O; von Bühler, CJ; Wilkinson, G; Zurth, C	1
Bachmann, A; Becker, A; Biedert, H; Bytyqi, A; Heuer, J; Hirt, S; Krebs-Brown, A; Lüpfert, C; Perrin, D; Strotmann, R; Vetter, C; Yalkinoglu, Ö	1

Trials

1 trial(s) available for midazolam and dabigatran

Article	Year
Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies. European journal of drug metabolism and pharmacokinetics, 2019, Volume: 44, Issue:6 Topics: Aged; Cells, Cultured; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme System; Dabigatran; Drug Interactions; Enzyme Induction; Female; Humans; Itraconazole; Male; Membrane Transport Proteins; Microsomes, Liver; Midazolam; Middle Aged; Pyrazoles; Rifampin; Rosuvastatin Calcium	2019

Article

Year

Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.

European journal of drug metabolism and pharmacokinetics, 2019, Volume: 44, Issue:6

Topics: Aged; Cells, Cultured; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme System; Dabigatran; Drug Interactions; Enzyme Induction; Female; Humans; Itraconazole; Male; Membrane Transport Proteins; Microsomes, Liver; Midazolam; Middle Aged; Pyrazoles; Rifampin; Rosuvastatin Calcium

2019

Other Studies

2 other study(ies) available for midazolam and dabigatran

Article	Year
Microdosing Cocktail Assay Development for Drug-Drug Interaction Studies. Journal of pharmaceutical sciences, 2018, Volume: 107, Issue:7 Topics: Antithrombins; Chromatography, Reverse-Phase; Cytochrome P-450 CYP3A; Dabigatran; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypnotics and Sedatives; Limit of Detection; Midazolam; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry	2018
Assessment of the potential of the MET inhibitor tepotinib to affect the pharmacokinetics of CYP3A4 and P-gp substrates. Investigational new drugs, 2023, Volume: 41, Issue:4 Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dabigatran; Drug Interactions; Humans; Lung Neoplasms; Midazolam	2023

Article

Year

Microdosing Cocktail Assay Development for Drug-Drug Interaction Studies.

Journal of pharmaceutical sciences, 2018, Volume: 107, Issue:7

Topics: Antithrombins; Chromatography, Reverse-Phase; Cytochrome P-450 CYP3A; Dabigatran; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypnotics and Sedatives; Limit of Detection; Midazolam; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry

2018

Assessment of the potential of the MET inhibitor tepotinib to affect the pharmacokinetics of CYP3A4 and P-gp substrates.

Investigational new drugs, 2023, Volume: 41, Issue:4

Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dabigatran; Drug Interactions; Humans; Lung Neoplasms; Midazolam

2023